title: Imidazoline binding sites in Huntington's and Parkinson's disease putamen.
abstract: Binding of [3H]2-(2-benzofuranyl)-2-imidazoline ([3H]BFI) to the imidazoline I2 receptor was determined in putamen taken post mortem from patients with two extrapyramidal motor disorders, Parkinson's and Huntington's diseases, and age-matched control subjects. No deficit of binding was apparent in Parkinson's disease, indicating that the receptors are not present on nigrostriatal terminals. A significant loss (by 56%) in imidazoline I2 receptor binding was observed in Huntington's disease, consistent with the receptors being sited on degenerating neurons.
authors.affiliation: Department of Biomedical Science, University of Sheffield, UK.
authors.forename: G P
authors.initials: GP
authors.lastname: Reynolds
authors.forename: R M
authors.initials: RM
authors.lastname: Boulton
authors.forename: S J
authors.initials: SJ
authors.lastname: Pearson
authors.forename: A L
authors.initials: AL
authors.lastname: Hudson
authors.forename: D J
authors.initials: DJ
authors.lastname: Nutt
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000493:pharmacokinetics; D001923:Brain Chemistry / Q000502:physiology*; D006801:Humans; D006816:Huntington Disease / Q000378:metabolism*; D019329:Idazoxan / Q000493:pharmacokinetics; D054755:Imidazoline Receptors; D010300:Parkinson Disease / Q000378:metabolism*; D011699:Putamen / Q000187:drug effects / Q000378:metabolism; D011955:Receptors, Drug / Q000187:drug effects / Q000378:metabolism*
chemical_list: D000317:Adrenergic alpha-Antagonists; D054755:Imidazoline Receptors; D011955:Receptors, Drug; D019329:Idazoxan